Shareholder Return Policy
The Company's basic policy is to continue paying stable dividends while comprehensively considering factors such
as securing funds to prepare for long-term business development. Furthermore, the Company uses its retained
earnings for R&D investments, production equipment investments, and other measures to strengthen its corporate
structure for sustainable future growth. On the other hand, the Company recognizes that providing fair profit returns
in line with earnings is also an important management priority.
Up to FY2025, based on the “ASKA Pharmaceutical Holdings Takes Action to Implement Management That is Conscious of Cost of Capital and Share Price” announced in November 2023, the Company targeted a consolidated payout ratio of 30%, with a minimum annual dividend per share of 30 yen.
From FY2026 onward, the Company targets a total payout ratio of 40% and has adopted a progressive dividend policy (excluding special dividends).
Dividends in the Current and the Following Period
Based on this policy and taking into account recent business performance, the year-end dividend for the fiscal year ended March 31, 2026, was set at ¥33 per share. Together with the interim dividend of ¥27 per share already paid, the annual dividend amounted to ¥60 per share.
For the fiscal year ending March 31, 2027, the Company plans to pay an annual dividend of ¥65 per share, consisting of an interim dividend of ¥32 per share and a year-end dividend of ¥33 per share, in accordance with the above policy.